9.55

0.21% 0.02

After Hours: 9.55

Nurix Therapeutics Inc (NRIX)

Overview News Price History Option Chain Financials Discussions Forecast

Nurix Therapeutics Inc stock is traded at $9.55, with a volume of 447.61K. It is up +0.21% in the last 24 hours and down -17.10% over the past month. Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.

Previous Close:

$9.53

Open:

$9.55

24h Volume:

447.61K

Relative Volume:

0.55

Market Cap:

$730.09M

Revenue:

$54.55M

Net Income/Loss:

$-193.57M

P/E Ratio:

-3.3045

EPS:

-2.89

Net Cash Flow:

$-181.86M

1W Performance:

+0.21%

1M Performance:

-17.10%

6M Performance:

-36.33%

1Y Performance:

-61.16%

1-Day Range:

$9.51

$9.72

1-Week Range:

$9.28

$10.33

52-Week Range:

$8.18

$29.56

Nurix Therapeutics Inc Stock (NRIX) Company Profile

Name

Nurix Therapeutics Inc

Sector

Healthcare (1146)

Industry

Biotechnology (644)

Phone

(415) 660-5320

Address

1700 OWENS STREET, SUITE 205, SAN FRANCISCO

Employee

286

Twitter

Next Earnings Date

2025-04-09

Latest SEC Filings

NRIX's Discussions on Twitter

Compare NRIX with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
NRIX Nurix Therapeutics Inc	9.55	728.56M	54.55M	-193.57M	-181.86M	-2.89
VRTX Vertex Pharmaceuticals Inc	389.08	99.27B	11.39B	3.64B	3.50B	13.99
REGN Regeneron Pharmaceuticals Inc	586.96	62.28B	14.21B	4.46B	3.56B	39.68
ALNY Alnylam Pharmaceuticals Inc	454.18	59.14B	2.46B	-319.09M	-52.09M	-2.47
ARGX Argen X Se Adr	707.96	43.34B	3.06B	1.28B	447.35M	21.30
ONC Beone Medicines Ltd Adr	300.14	36.72B	3.81B	-644.79M	-669.77M	-6.24

Nurix Therapeutics Inc Stock (NRIX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-17-25	Initiated	Leerink Partners	Market Perform
Dec-10-24	Initiated	BTIG Research	Buy
Dec-06-24	Initiated	BMO Capital Markets	Outperform
Oct-24-24	Initiated	UBS	Buy
Oct-11-24	Initiated	Jefferies	Buy
Sep-06-24	Resumed	Robert W. Baird	Outperform
Jul-31-24	Initiated	Truist	Buy
Jun-26-23	Resumed	Oppenheimer	Outperform
Mar-09-23	Initiated	Barclays	Overweight
Feb-28-23	Initiated	Oppenheimer	Outperform
Oct-11-22	Initiated	Morgan Stanley	Equal-Weight
May-31-22	Upgrade	Wells Fargo	Equal Weight → Overweight
Feb-10-22	Initiated	Wells Fargo	Equal Weight
Dec-29-21	Initiated	H.C. Wainwright	Buy
Oct-14-21	Initiated	SVB Leerink	Outperform
Jun-04-21	Resumed	Robert W. Baird	Outperform
Apr-30-21	Resumed	Piper Sandler	Overweight
Apr-30-21	Initiated	RBC Capital Mkts	Outperform
Apr-14-21	Initiated	Berenberg	Buy
Nov-19-20	Initiated	Robert W. Baird	Outperform
Aug-18-20	Initiated	JP Morgan	Overweight
Aug-18-20	Initiated	Needham	Buy
Aug-18-20	Initiated	Piper Sandler	Overweight
Aug-18-20	Initiated	Stifel	Buy

View All

Nurix Therapeutics Inc Stock (NRIX) Latest News

Aug 27, 2025

Candriam S.C.A. Sells 45,695 Shares of Nurix Therapeutics, Inc. $NRIX - MarketBeat

Aug 27, 2025